The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and ...

Some of the more than a dozen states that cover GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy will have the option to buy now and pay later under a partnership announced Tuesday by ...

The days of cheaper alternatives to popular weight-loss drugs like Wegovy and Zepbound are over for some Long Islanders and are numbered for others, pharmacists and compounding industry groups say.

As the popularity of Ozempic, Victoza, Wegovy and other GLP-1 agonists have continued to increase, ... More so have restrictions on insurance coverage for many of them. (Photo by: Michael Siluk ...